600276 恒瑞医药
交易中 12-05 13:29:46
资讯
新帖
简况
富时中国50指数调整：纳入中国宏桥(01378)、宁德时代(03750)、恒瑞医药(01276)，剔除中信建投证券(06066)等
智通财经 · 12-03 18:40
富时中国50指数调整：纳入中国宏桥(01378)、宁德时代(03750)、恒瑞医药(01276)，剔除中信建投证券(06066)等
恒瑞医药最新公告：董事会提名聘任朱国新为公司高级副总裁
证券之星 · 12-03 17:34
恒瑞医药最新公告：董事会提名聘任朱国新为公司高级副总裁
恒瑞医药回购890万股 金额5.95亿元
财中社 · 12-02 17:37
恒瑞医药回购890万股 金额5.95亿元
GIC Private Limited增持恒瑞医药(01276)42.24万股 每股作价约74.96港元
智通财经 · 12-01
GIC Private Limited增持恒瑞医药(01276)42.24万股 每股作价约74.96港元
恒瑞医药获大摩增持约177.06万股 每股均价69.65港元
新浪港股 · 11-28
恒瑞医药获大摩增持约177.06万股 每股均价69.65港元
Wellington Management Group LLP增持恒瑞医药(01276)100万股 每股作价69.15港元
智通财经网 · 11-26
Wellington Management Group LLP增持恒瑞医药(01276)100万股 每股作价69.15港元
港股恒瑞医药涨超5%
每日经济新闻 · 11-26
港股恒瑞医药涨超5%
恒瑞医药(600276.SH)：HRS-8364片获准开展临床试验
智通财经 · 11-25
恒瑞医药(600276.SH)：HRS-8364片获准开展临床试验
恒瑞医药(600276.SH)：硫酸艾玛昔替尼片上市许可申请获受理
智通财经网 · 11-24
恒瑞医药(600276.SH)：硫酸艾玛昔替尼片上市许可申请获受理
港股异动 | 恒瑞医药(01276)涨超5% 注射用SHR-9839等9款药物获批开展临床试验
智通财经 · 11-24
港股异动 | 恒瑞医药(01276)涨超5% 注射用SHR-9839等9款药物获批开展临床试验
每周股票复盘：恒瑞医药（600276）获多项临床试验批准
证券之星 · 11-23
每周股票复盘：恒瑞医药（600276）获多项临床试验批准
恒瑞医药(01276)11月21日耗资约1487.99万港元回购25万股
智通财经 · 11-21
恒瑞医药(01276)11月21日耗资约1487.99万港元回购25万股
恒瑞医药：注射用SHR-9839(sc)获临床试验批准
南方财经网 · 11-21
恒瑞医药：注射用SHR-9839(sc)获临床试验批准
摩根士丹利在恒瑞医药H股的多头头寸于11月18日上升至6.48%
美股速递 · 11-21
摩根士丹利在恒瑞医药H股的多头头寸于11月18日上升至6.48%
恒瑞医药(01276)11月20日斥资1274.32万元回购20.99万股A股
智通财经 · 11-20
恒瑞医药(01276)11月20日斥资1274.32万元回购20.99万股A股
港股异动 | 恒瑞医药(01276)涨近3% 富马酸泰吉利定注射液临床试验获批
智通财经 · 11-18
港股异动 | 恒瑞医药(01276)涨近3% 富马酸泰吉利定注射液临床试验获批
恒瑞医药(600276.SH)：HRS-4642注射液等多款药物获得临床试验批准
智通财经 · 11-17
恒瑞医药(600276.SH)：HRS-4642注射液等多款药物获得临床试验批准
每周股票复盘：恒瑞医药（600276）大宗交易机构净卖出3601.8万元
证券之星 · 11-16
每周股票复盘：恒瑞医药（600276）大宗交易机构净卖出3601.8万元
恒瑞医药(01276)：2022年员工持股计划第三个锁定期实际解锁股份共计283.03万股
智通财经 · 11-14
恒瑞医药(01276)：2022年员工持股计划第三个锁定期实际解锁股份共计283.03万股
奥泰生物、奥浦迈生物、恒瑞医药高管同台探讨：中国何时诞生世界级医药企业？
新浪证券 · 11-13
奥泰生物、奥浦迈生物、恒瑞医药高管同台探讨：中国何时诞生世界级医药企业？
加载更多
公司概况
公司名称：
江苏恒瑞医药股份有限公司
所属行业：
医药制造业
上市日期：
2000-10-18
主营业务：
江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是硫培非格司亭注射液、马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇胺片、碘佛醇注射液。
发行价格：
11.98
{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":61.25,"timestamp":1764912586000,"preClose":61.25,"halted":0,"volume":12103821,"delay":0,"changeRate":0,"floatShares":6379000000,"shares":6637000000,"eps":1.1252,"marketStatus":"交易中","change":0,"latestTime":"12-05 13:29:46","open":61.19,"high":61.41,"low":60.7,"amount":740000000,"amplitude":0.0116,"askPrice":61.25,"askSize":53,"bidPrice":61.24,"bidSize":51,"shortable":0,"etf":0,"ttmEps":1.1252,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1764918000000},"marketStatusCode":2,"adr":0,"adjPreClose":61.25,"symbolType":"stock","openAndCloseTimeList":[[1764898200000,1764905400000],[1764910800000,1764918000000]],"highLimit":67.38,"lowLimit":55.13,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637199874,"isCdr":false,"pbRate":6.83,"roa":"--","peRate":54.434767,"roe":"11.09%","epsLYR":1,"committee":0.002433,"marketValue":406528000000,"turnoverRate":0.0019,"status":2,"hkstockBrief":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":73.2,"timestamp":1764912475774,"preClose":72.9,"halted":0,"volume":825555,"delay":0,"premium":"+8.53"},"floatMarketCap":390714000000},"requestUrl":"/m/hq/s/600276","defaultTab":"news","newsList":[{"id":"2588109870","title":"富时中国50指数调整：纳入中国宏桥(01378)、宁德时代(03750)、恒瑞医药(01276)，剔除中信建投证券(06066)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2588109870","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588109870?lang=zh_cn&edition=full","pubTime":"2025-12-03 18:40","pubTimestamp":1764758405,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，12月3日，富时罗素宣布对富时中国50指数、富时中国A50指数、富时中国A150指数、富时中国A200指数及富时中国A400指数进行审议调整，该调整将于2025年12月19日(星期五)收盘后生效。其中，本次富时中国50指数成分股将纳入中国宏桥、宁德时代、恒瑞医药等港股，将剔除中信建投证券H股、长城汽车H股、理想汽车-W等港股公司。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377153.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01378","LU0140636845.USD","LU1224709979.USD","LU1781817850.SGD","LU0011963245.USD","LU1166156734.SGD","BK0239","03750","LU0516422440.USD","LU1861214812.USD","LU0359201612.USD","LU0328353924.USD","LU0531971595.HKD","EVS.SI","LU0594300179.USD","LU0463099449.HKD","LU2506952410.USD","LU1152091168.USD","LU2506951792.HKD","LU0651946864.USD","JKS","LU2580892789.USD","LU0039217434.USD","LU0231483743.USD","LU0072462343.USD","LU0651947912.USD","LU1979443071.USD","LU0302445910.USD","LU1934453819.USD","IE00B8L5B284.USD","LU0880133367.SGD","LU2348774022.SGD","LU2495084118.USD","LU1719994722.HKD","300750","LU0106252389.USD","01276","600276","LU0107464264.USD","LU1064131003.USD","LU0326950275.SGD","LU0611395673.USD","LU0702159699.USD","LU1861219969.SGD","LU1794554557.SGD","BK1500","BK4526","06066","LU0821914370.USD","LU1720050803.USD"],"gpt_icon":0},{"id":"2588014759","title":"恒瑞医药最新公告：董事会提名聘任朱国新为公司高级副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2588014759","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588014759?lang=zh_cn&edition=full","pubTime":"2025-12-03 17:34","pubTimestamp":1764754490,"startTime":"0","endTime":"0","summary":"恒瑞医药公告称，公司第九届董事会第二十次会议于2025年12月3日召开，会议审议并通过了《关于提名聘任公司高级副总裁的议案》，提名聘任朱国新为公司高级副总裁，任期自本次董事会审议通过之日起至本届董事会任期届满为止。朱国新拥有30余年全球跨职能药物发现领导经验，涉及多个疾病领域。加入恒瑞医药前，他在礼来新药研发中心担任副总裁，领导了多个发现研究和早期开发项目。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300027544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","LU1328615791.USD","LU0405327148.USD","LU2495084118.USD","LU2488822045.USD","LU1146622755.USD","LU1969619763.USD","LU1997245094.SGD","LU2580892789.USD","LU2097828714.EUR","LU1997244956.HKD","LU0359202008.SGD","LU2543165471.USD","BK0239","LU1781817850.SGD","LU1064130708.USD","LU2148510915.USD","LU1064131003.USD","BK0196","LU2580892862.HKD","BK1191","LU1997245177.USD","LU1820825898.SGD","LU0359201612.USD","BK0183","01276","LU2097828805.USD","LU0405327494.USD","LU1655091616.SGD","LU2097828474.EUR","LU2328871848.SGD","BK0060","LU1255011170.USD","BK0012","LU1023057109.AUD","LU2097828557.USD","LU2097828631.EUR","LU2289578879.USD","600276","LU0359201885.HKD","LU1580142542.USD"],"gpt_icon":0},{"id":"2588398720","title":"恒瑞医药回购890万股 金额5.95亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588398720","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588398720?lang=zh_cn&edition=full","pubTime":"2025-12-02 17:37","pubTimestamp":1764668274,"startTime":"0","endTime":"0","summary":"12月2日，恒瑞医药（600276/01276）发布公告，截至2025年11月30日已回购890万股，占总股本的0.13%，回购资金总额为5.95亿元，回购价格区间为59.32元/股至70元/股。2025年前三季度，恒瑞医药实现收入231.88亿元，归母净利润57.51亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512023580451214.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1997244956.HKD","BK0183","LU0405327494.USD","BK0060","LU2289578879.USD","LU2097828714.EUR","BK0012","LU1023057109.AUD","01276","LU1997245094.SGD","LU1997245177.USD","LU2543165471.USD","LU2097828474.EUR","LU2488822045.USD","LU2148510915.USD","LU1064130708.USD","LU2495084118.USD","LU2097828805.USD","LU2328871848.SGD","LU1580142542.USD","600276","BK0239","LU1064131003.USD","LU2580892789.USD","LU1146622755.USD","LU2580892862.HKD","BK0196","LU1655091616.SGD","LU0359202008.SGD","BK0028","LU1328615791.USD","LU1781817850.SGD","LU2097828631.EUR","LU1255011170.USD","BK0188","LU1820825898.SGD","BK1191","LU2097828557.USD","LU1969619763.USD","LU0359201612.USD","LU0405327148.USD","LU0359201885.HKD"],"gpt_icon":0},{"id":"2588727841","title":"GIC Private Limited增持恒瑞医药(01276)42.24万股 每股作价约74.96港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588727841","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588727841?lang=zh_cn&edition=full","pubTime":"2025-12-01 20:27","pubTimestamp":1764592054,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，11月27日，GIC Private Limited增持恒瑞医药(01276)42.24万股，每股作价74.955港元，总金额约为3166.1万港元。增持后最新持股数目为5946.22万股，最新持股比例为23.03%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1376177.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0405327148.USD","LU1997245177.USD","LU2328871848.SGD","LU1580142542.USD","LU2488822045.USD","LU1064131003.USD","BK0183","LU1328615791.USD","LU2495084118.USD","LU1781817850.SGD","LU0359201612.USD","LU2097828557.USD","LU0405327494.USD","BK0028","LU1655091616.SGD","BK0188","BK0060","LU0359202008.SGD","BK4104","LU2097828805.USD","LU2543165471.USD","LU1255011170.USD","LU2097828714.EUR","LU2148510915.USD","BK0196","LU0359201885.HKD","LU2289578879.USD","LU2097828631.EUR","GIC","LU1969619763.USD","LU1997244956.HKD","LU1997245094.SGD","LU2580892862.HKD","BK0239","LU1064130708.USD","600276","LU1023057109.AUD","BK0012","LU1820825898.SGD","LU2097828474.EUR","01276","LU2580892789.USD","LU1146622755.USD","BK1191"],"gpt_icon":0},{"id":"2586127392","title":"恒瑞医药获大摩增持约177.06万股 每股均价69.65港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586127392","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586127392?lang=zh_cn&edition=full","pubTime":"2025-11-28 07:27","pubTimestamp":1764286020,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 香港联交所最新资料显示，11月24日，大摩增持恒瑞医药（01276）177.0645万股，每股均价69.65港元，总金额约为1.23亿港元。增持后最新持股数目约为2084.8万股，最新持股比例为8.07%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-11-28/doc-infywyzq8672404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1668664300.SGD","LU1244550494.USD","LU0359202008.SGD","LU1023057109.AUD","IE00BZ1G4Q59.USD","600276","LU1255011170.USD","LU1969619763.USD","LU1074936037.SGD","BK0183","LU2097828714.EUR","LU1820825898.SGD","LU1162221912.USD","BK0196","BK4534","LU1720051017.SGD","LU1720051108.HKD","LU2148510915.USD","LU2580892862.HKD","LU2328871848.SGD","BK4588","LU0006306889.USD","LU1655091616.SGD","LU0405327148.USD","LU2289578879.USD","LU0359201612.USD","BK0012","LU1244550221.USD","BK4516","BK0028","LU2543165471.USD","LU1997245094.SGD","LU0234570918.USD","LU0359201885.HKD","LU2133065610.SGD","LU2357305700.SGD","LU0225283273.USD","LU1328615791.USD","LU2028103732.USD","LU0158827781.USD","01276","LU1064130708.USD","LU2580892789.USD","BK0188","LU0314104364.USD","LU0528227936.USD","LU1791710582.SGD","LU2097828557.USD","BK1191","LU1732800096.USD"],"gpt_icon":0},{"id":"2586325984","title":"Wellington Management Group LLP增持恒瑞医药(01276)100万股 每股作价69.15港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586325984","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586325984?lang=zh_cn&edition=full","pubTime":"2025-11-26 19:00","pubTimestamp":1764154804,"startTime":"0","endTime":"0","summary":"11月24日，Wellington Management Group LLP增持恒瑞医药(01276)100万股，每股作价69.15港元，总金额为6915万港元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20251126/20251126190042_87547.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251126/20251126190042_87547.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374017.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1064131003.USD","LU0405327494.USD","LU2097828714.EUR","LU1997244956.HKD","600276","LU0359201612.USD","LU1969619763.USD","LU1255011170.USD","LU1781817850.SGD","BK0239","LU2097828805.USD","LU1997245094.SGD","LU2097828557.USD","LU2328871848.SGD","LU2148510915.USD","LU1064130708.USD","LU2580892862.HKD","LU2488822045.USD","LU2495084118.USD","LU2580892789.USD","LU2097828631.EUR","BK0012","LU1023057109.AUD","LU1146622755.USD","LU2543165471.USD","BK0188","LU1820825898.SGD","LU1580142542.USD","BK0183","LU2289578879.USD","BK0028","01276","LU1655091616.SGD","LU1328615791.USD","LU0359202008.SGD","LU1997245177.USD","LU2097828474.EUR","BK0060","LU0359201885.HKD","LU0405327148.USD","BK0196","BK1191"],"gpt_icon":0},{"id":"2586228169","title":"港股恒瑞医药涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586228169","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586228169?lang=zh_cn&edition=full","pubTime":"2025-11-26 10:26","pubTimestamp":1764123973,"startTime":"0","endTime":"0","summary":"每经AI快讯，恒瑞医药(01276.HK)涨超5%，截至发稿，涨5.61%，报74.3港元，成交额1.26亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511263575197554.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511263575197554.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0359201885.HKD","LU1023057109.AUD","LU2097828557.USD","LU1146622755.USD","BK0188","LU2097828714.EUR","LU1781817850.SGD","BK1191","LU2580892862.HKD","LU2148510915.USD","LU1820825898.SGD","LU1997245094.SGD","LU2097828474.EUR","LU2097828805.USD","LU1655091616.SGD","LU1064130708.USD","BK0028","LU1580142542.USD","LU2580892789.USD","BK0183","LU2289578879.USD","LU1969619763.USD","LU2543165471.USD","LU2488822045.USD","BK0239","BK0012","BK0060","01276","LU2097828631.EUR","LU1997244956.HKD","600276","BK0196","LU2328871848.SGD","LU0405327148.USD","LU0405327494.USD","LU1255011170.USD","LU0359202008.SGD","LU1064131003.USD","LU0359201612.USD","LU2495084118.USD","LU1997245177.USD","LU1328615791.USD"],"gpt_icon":0},{"id":"2586355423","title":"恒瑞医药(600276.SH)：HRS-8364片获准开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2586355423","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586355423?lang=zh_cn&edition=full","pubTime":"2025-11-25 16:47","pubTimestamp":1764060461,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)公告，公司收到国家药品监督管理局核准签发关于HRS-8364片的《药物临床试验批准通知书》，将于近期开展临床试验。HRS-8364片是公司自主研发的创新型抗肿瘤药物，拟用于治疗晚期实体瘤。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373284.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1997245177.USD","LU2148510915.USD","LU0405327148.USD","LU0405327494.USD","BK0239","LU1580142542.USD","BK0188","LU2488822045.USD","LU1969619763.USD","BK0012","BK0028","LU2097828631.EUR","LU1023057109.AUD","BK0183","LU0359202008.SGD","LU2097828557.USD","01276","BK1191","LU1328615791.USD","LU2097828714.EUR","LU2495084118.USD","LU1820825898.SGD","LU1781817850.SGD","LU1255011170.USD","LU1655091616.SGD","LU2097828805.USD","600276","LU2328871848.SGD","BK0196","BK0060","LU1146622755.USD","LU1064130708.USD","LU1997244956.HKD","LU0359201885.HKD","LU2289578879.USD","LU2543165471.USD","LU2580892862.HKD","LU2580892789.USD","LU1064131003.USD","LU2097828474.EUR","LU0359201612.USD","LU1997245094.SGD"],"gpt_icon":0},{"id":"2585457922","title":"恒瑞医药(600276.SH)：硫酸艾玛昔替尼片上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2585457922","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585457922?lang=zh_cn&edition=full","pubTime":"2025-11-24 17:07","pubTimestamp":1763975245,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，公司收到国家药品监督管理局下发的《受理通知书》，公司提交的硫酸艾玛昔替尼片药品上市许可申请获国家药监局受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372741.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1997245094.SGD","BK0183","LU1255011170.USD","BK1191","LU1820825898.SGD","LU0405327494.USD","01276","LU1969619763.USD","LU1997245177.USD","600276","BK0196","LU2543165471.USD","LU2097828474.EUR","LU2097828631.EUR","LU0359202008.SGD","LU2580892789.USD","BK0028","LU1997244956.HKD","LU1023057109.AUD","LU2097828557.USD","LU2488822045.USD","LU2097828714.EUR","LU0405327148.USD","LU2495084118.USD","LU1580142542.USD","LU2097828805.USD","LU1064131003.USD","LU1146622755.USD","LU1328615791.USD","LU0359201612.USD","LU1781817850.SGD","BK0060","LU1064130708.USD","LU2580892862.HKD","BK0012","LU0359201885.HKD","LU2289578879.USD","LU2328871848.SGD","LU2148510915.USD","BK0188","BK0239","LU1655091616.SGD"],"gpt_icon":0},{"id":"2585319694","title":"港股异动 | 恒瑞医药(01276)涨超5% 注射用SHR-9839等9款药物获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2585319694","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585319694?lang=zh_cn&edition=full","pubTime":"2025-11-24 09:47","pubTimestamp":1763948877,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，恒瑞医药(01276)涨超5%，截至发稿，涨5.08%，报69.3港元，成交额1.41亿港元。消息面上，11月21日，恒瑞医药发布公告，近日，江苏恒瑞医药股份有限公司及子公司苏州盛迪亚生物医药有限公司、上海恒瑞医药有限公司、上海盛迪医药有限公司收到国家药品监督管理局核准签发关于注射用SHR-9839(sc)、注射用SHR-A2009、注射用SHR-1826、HRS-4642注射液、阿得贝利单抗注射液、注射用瑞康曲妥珠单抗、注射用SHR-A2102、HRS-7058胶囊和HRS-7058片的《药物临床试验批准通知书》，将于近期开展临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372550.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828557.USD","LU0359201612.USD","LU2328871848.SGD","LU1997245177.USD","LU2488822045.USD","LU1023057109.AUD","LU2543165471.USD","LU1255011170.USD","LU1997245094.SGD","LU1997244956.HKD","BK0060","BK0239","LU1064131003.USD","LU2495084118.USD","LU0405327494.USD","LU1580142542.USD","600276","BK1191","LU1655091616.SGD","01276","LU1328615791.USD","LU1969619763.USD","BK0183","LU2580892789.USD","LU1820825898.SGD","LU2097828714.EUR","LU2289578879.USD","LU2580892862.HKD","LU0405327148.USD","BK0196","LU2097828805.USD","LU0359202008.SGD","LU0359201885.HKD","LU2097828474.EUR","BK0012","LU1064130708.USD","BK0028","LU1781817850.SGD","LU1146622755.USD","LU2148510915.USD","LU2097828631.EUR","BK0188"],"gpt_icon":0},{"id":"2585108093","title":"每周股票复盘：恒瑞医药（600276）获多项临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2585108093","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585108093?lang=zh_cn&edition=full","pubTime":"2025-11-23 02:03","pubTimestamp":1763834593,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，恒瑞医药报收于59.5元，较上周的62.9元下跌5.41%。本周关注点公司公告汇总：恒瑞医药及子公司获多项药物临床试验批准，涉及抗肿瘤、镇痛等领域。恒瑞医药及子公司山东盛迪医药有限公司获HRS-6209胶囊、HRS-2189片《药物临床试验批准通知书》，同意联合HRS-2189和芳香化酶抑制剂用于乳腺癌的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","LU0405327494.USD","LU2097828714.EUR","LU1997244956.HKD","600276","LU0359201612.USD","LU1969619763.USD","LU1255011170.USD","LU1781817850.SGD","BK0239","LU2097828805.USD","LU1997245094.SGD","LU2097828557.USD","LU2328871848.SGD","LU2148510915.USD","LU1064130708.USD","LU2580892862.HKD","LU2488822045.USD","LU2495084118.USD","LU2580892789.USD","LU2097828631.EUR","BK0012","LU1023057109.AUD","LU1146622755.USD","LU2543165471.USD","BK0188","LU1820825898.SGD","LU1580142542.USD","BK0183","LU2289578879.USD","BK0028","01276","LU1655091616.SGD","LU1328615791.USD","LU0359202008.SGD","LU1997245177.USD","LU2097828474.EUR","BK0060","LU0359201885.HKD","LU0405327148.USD","BK0196","BK1191"],"gpt_icon":0},{"id":"2585111942","title":"恒瑞医药(01276)11月21日耗资约1487.99万港元回购25万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2585111942","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585111942?lang=zh_cn&edition=full","pubTime":"2025-11-21 18:02","pubTimestamp":1763719333,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)公布，2025年11月21日耗资约1487.99万港元回购25万股股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372160.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600276","LU0405327148.USD","LU1023057109.AUD","LU2580892789.USD","LU1997245177.USD","LU2097828474.EUR","LU1146622755.USD","LU1997245094.SGD","LU0359201885.HKD","LU2495084118.USD","BK0196","LU2097828631.EUR","LU2289578879.USD","LU1064131003.USD","LU1580142542.USD","LU2148510915.USD","BK0060","BK0012","LU1781817850.SGD","LU1997244956.HKD","LU2488822045.USD","BK1191","LU1969619763.USD","LU2097828714.EUR","LU2097828557.USD","LU2580892862.HKD","BK0239","LU2097828805.USD","LU1655091616.SGD","LU1255011170.USD","LU1328615791.USD","BK0028","BK0183","LU2543165471.USD","01276","LU0359202008.SGD","BK0188","LU0359201612.USD","LU2328871848.SGD","LU1064130708.USD","LU0405327494.USD","LU1820825898.SGD"],"gpt_icon":0},{"id":"2585119050","title":"恒瑞医药：注射用SHR-9839(sc)获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2585119050","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585119050?lang=zh_cn&edition=full","pubTime":"2025-11-21 18:02","pubTimestamp":1763719323,"startTime":"0","endTime":"0","summary":"南财智讯11月21日电，恒瑞医药公告，恒瑞医药收到国家药品监督管理局核准签发的关于注射用SHR-9839(sc)的《药物临床试验批准通知书》，同意开展临床试验。该药品为公司自主研发的人源化抗体药物，拟用于治疗晚期实体瘤，通过同时阻断与肿瘤发生发展相关的两条关键信号通路发挥抗肿瘤作用。此次获批将开展一项在实体瘤受试者中评价其安全性、耐受性及有效性的IB/II期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511213571522627.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0196","LU1064130708.USD","LU1146622755.USD","LU2097828714.EUR","BK0239","600276","LU1580142542.USD","LU2097828631.EUR","LU2097828805.USD","LU0405327148.USD","LU2097828557.USD","LU1781817850.SGD","LU1997245094.SGD","LU2289578879.USD","LU0405327494.USD","BK0012","LU2580892789.USD","LU2097828474.EUR","01276","LU1655091616.SGD","LU2328871848.SGD","LU0359201885.HKD","BK1191","LU1820825898.SGD","BK0183","LU1328615791.USD","LU1023057109.AUD","LU1255011170.USD","LU2488822045.USD","LU0359202008.SGD","BK0028","LU2543165471.USD","LU2580892862.HKD","LU1969619763.USD","LU0359201612.USD","LU2148510915.USD","BK0188","LU1997245177.USD","LU1997244956.HKD","LU2495084118.USD","BK0060","LU1064131003.USD"],"gpt_icon":0},{"id":"1152757442","title":"摩根士丹利在恒瑞医药H股的多头头寸于11月18日上升至6.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152757442","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152757442?lang=zh_cn&edition=full","pubTime":"2025-11-21 17:13","pubTimestamp":1763716418,"startTime":"0","endTime":"0","summary":"摩根士丹利在恒瑞医药H股的多头头寸于11月18日从5.94%上升至6.48%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2148510915.USD","LU1064131003.USD","LU1969619763.USD","LU2580892862.HKD","LU2495084118.USD","BK0196","LU1023057109.AUD","LU1064130708.USD","LU2097828557.USD","BK0028","LU1255011170.USD","LU2543165471.USD","LU1146622755.USD","LU1580142542.USD","BK0183","LU1997244956.HKD","600276","LU1328615791.USD","LU2097828714.EUR","LU1997245094.SGD","LU1781817850.SGD","LU1997245177.USD","LU2488822045.USD","LU0359201885.HKD","LU2097828631.EUR","BK0012","LU0405327148.USD","BK0060","01276","BK0239","BK0188","LU2328871848.SGD","LU2580892789.USD","LU0359201612.USD","BK1191","LU2097828474.EUR","LU0359202008.SGD","LU1820825898.SGD","LU1655091616.SGD","LU0405327494.USD","LU2289578879.USD","LU2097828805.USD"],"gpt_icon":0},{"id":"2584189213","title":"恒瑞医药(01276)11月20日斥资1274.32万元回购20.99万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2584189213","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584189213?lang=zh_cn&edition=full","pubTime":"2025-11-20 16:34","pubTimestamp":1763627655,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，该公司于2025年11月20日斥资1274.32万元人民币回购20.99万股A股，每股回购价格为60.58-60.78元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1371560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828474.EUR","BK0183","LU1997245177.USD","LU0359201885.HKD","BK0012","LU2097828714.EUR","LU0405327494.USD","LU2495084118.USD","LU2097828557.USD","BK0028","LU1064131003.USD","BK0239","LU2488822045.USD","LU0359202008.SGD","BK0196","BK0060","LU1997245094.SGD","LU1969619763.USD","399300","600276","LU1781817850.SGD","LU1580142542.USD","01276","BK1191","LU0359201612.USD","159982","LU2543165471.USD","LU2289578879.USD","LU1023057109.AUD","BK0188","LU1064130708.USD","LU1820825898.SGD","LU1255011170.USD","LU1997244956.HKD","LU1146622755.USD","LU2097828805.USD","LU0405327148.USD","LU2148510915.USD","LU1328615791.USD","LU2580892862.HKD","LU2328871848.SGD","LU2097828631.EUR","LU1655091616.SGD","LU2580892789.USD"],"gpt_icon":0},{"id":"2584601355","title":"港股异动 | 恒瑞医药(01276)涨近3% 富马酸泰吉利定注射液临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2584601355","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584601355?lang=zh_cn&edition=full","pubTime":"2025-11-18 09:49","pubTimestamp":1763430579,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，恒瑞医药涨近3%，截至发稿，涨1.76%，报72.35港元，成交额3758.86万港元。消息面上，11月17日，恒瑞医药发布公告，江苏恒瑞医药股份有限公司收到国家药品监督管理局核准签发关于富马酸泰吉利定注射液的《药物临床试验批准通知书》，将于近期开展临床试验。截至目前，富马酸泰吉利定注射液相关项目累计研发投入约2亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828557.USD","LU2580892789.USD","BK0028","BK0188","LU0359202008.SGD","LU2097828474.EUR","LU2328871848.SGD","LU0405327494.USD","LU1820825898.SGD","LU2289578879.USD","LU1997245094.SGD","LU1997244956.HKD","600276","BK0196","01276","LU2097828714.EUR","BK0060","LU1064130708.USD","LU1781817850.SGD","LU1023057109.AUD","LU1146622755.USD","LU2495084118.USD","LU0405327148.USD","LU1255011170.USD","BK0012","LU0359201885.HKD","LU1969619763.USD","LU1997245177.USD","LU2097828805.USD","LU2148510915.USD","LU2488822045.USD","LU2097828631.EUR","BK1191","LU1580142542.USD","BK0183","LU1328615791.USD","LU1655091616.SGD","BK0239","LU2543165471.USD","LU1064131003.USD","LU2580892862.HKD","LU0359201612.USD"],"gpt_icon":0},{"id":"2584481376","title":"恒瑞医药(600276.SH)：HRS-4642注射液等多款药物获得临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2584481376","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584481376?lang=zh_cn&edition=full","pubTime":"2025-11-17 16:17","pubTimestamp":1763367456,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司及子公司苏州盛迪亚生物医药有限公司、上海恒瑞医药有限公司、上海盛迪医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于HRS-4642注射液、 SHR-1701 注射液、SHR-7367 注射液、SHR-8068 注射液、阿得贝利单抗注射液、贝伐珠单抗注射液、注射用SHR-A2102、苹果酸法米替尼胶囊和羟乙磺酸达尔西利片的《药物临床试验批准通知书》，将于近期开展临床试验。具体为：一项HRS-4642联合抗肿瘤药物在实体瘤受试者中的安全性、耐受性及有效性的ⅠB/Ⅱ期研究方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369956.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1997245177.USD","LU2148510915.USD","LU0405327148.USD","LU0405327494.USD","BK0239","LU1580142542.USD","BK0188","LU2488822045.USD","LU1969619763.USD","BK0012","BK0028","LU2097828631.EUR","LU1023057109.AUD","BK0183","LU0359202008.SGD","LU2097828557.USD","01276","BK1191","LU1328615791.USD","LU2097828714.EUR","LU2495084118.USD","LU1820825898.SGD","LU1781817850.SGD","LU1255011170.USD","LU1655091616.SGD","LU2097828805.USD","600276","LU2328871848.SGD","BK0196","BK0060","LU1146622755.USD","LU1064130708.USD","LU1997244956.HKD","LU0359201885.HKD","LU2289578879.USD","LU2543165471.USD","LU2580892862.HKD","LU2580892789.USD","LU1064131003.USD","LU2097828474.EUR","LU0359201612.USD","LU1997245094.SGD"],"gpt_icon":0},{"id":"2583441656","title":"每周股票复盘：恒瑞医药（600276）大宗交易机构净卖出3601.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583441656","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583441656?lang=zh_cn&edition=full","pubTime":"2025-11-16 01:27","pubTimestamp":1763227629,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，恒瑞医药报收于62.9元，较上周的61.58元上涨2.14%。本周关注点交易信息汇总：11月12日恒瑞医药现1笔大宗交易，机构净卖出3601.8万元 公司公告汇总：恒瑞医药连续两日回购A股，合计21万股用于员工持股计划 公司公告汇总：瑞维鲁胺片获准开展前列腺癌Ⅲ期临床试验 公司公告汇总：2022年员工持股计划第三个锁定期解锁执行完毕 交易信息汇总11月12日恒瑞医药发生1笔大宗交易，机构专用账户净卖出3601.8万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000195.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","LU2580892789.USD","BK0183","LU2328871848.SGD","BK0196","LU2097828631.EUR","LU1146622755.USD","LU2488822045.USD","LU0405327148.USD","BK0012","LU0359201612.USD","LU1781817850.SGD","LU1997245094.SGD","LU2097828474.EUR","LU0359202008.SGD","LU2097828714.EUR","LU2097828805.USD","BK0060","LU1580142542.USD","LU1655091616.SGD","LU1820825898.SGD","LU1997245177.USD","LU1064130708.USD","LU2543165471.USD","LU1064131003.USD","LU2148510915.USD","LU2580892862.HKD","600276","LU0405327494.USD","BK0028","LU1255011170.USD","BK0239","LU1023057109.AUD","LU1997244956.HKD","LU2097828557.USD","LU0359201885.HKD","LU2495084118.USD","LU1969619763.USD","BK1191","LU1328615791.USD","LU2289578879.USD","01276"],"gpt_icon":0},{"id":"2583571976","title":"恒瑞医药(01276)：2022年员工持股计划第三个锁定期实际解锁股份共计283.03万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2583571976","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583571976?lang=zh_cn&edition=full","pubTime":"2025-11-14 17:39","pubTimestamp":1763113177,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，截至本公告披露日，公司2022年员工持股计划第三个锁定期实际解锁股份共计283.03万股(占目前公司总股本的0.04%)。截至2025年11月14日，165.68万股非交易过户至员工持股计划份额持有人，117.35万股通过集中竞价交易方式出售。公司2022年员工持股计划管理委员会后续将根据本次员工持股计划的相关约定进行相应财产分配工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369408.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600276","LU0405327148.USD","LU1023057109.AUD","LU2580892789.USD","LU1997245177.USD","LU2097828474.EUR","LU1146622755.USD","LU1997245094.SGD","LU0359201885.HKD","LU2495084118.USD","BK0196","LU2097828631.EUR","LU2289578879.USD","LU1064131003.USD","LU1580142542.USD","LU2148510915.USD","BK0060","BK0012","LU1781817850.SGD","LU1997244956.HKD","LU2488822045.USD","BK1191","LU1969619763.USD","LU2097828714.EUR","LU2097828557.USD","LU2580892862.HKD","BK0239","LU2097828805.USD","LU1655091616.SGD","LU1255011170.USD","LU1328615791.USD","BK0028","BK0183","LU2543165471.USD","01276","LU0359202008.SGD","BK0188","LU0359201612.USD","LU2328871848.SGD","LU1064130708.USD","LU0405327494.USD","LU1820825898.SGD"],"gpt_icon":0},{"id":"2583562646","title":"奥泰生物、奥浦迈生物、恒瑞医药高管同台探讨：中国何时诞生世界级医药企业？","url":"https://stock-news.laohu8.com/highlight/detail?id=2583562646","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583562646?lang=zh_cn&edition=full","pubTime":"2025-11-13 20:07","pubTimestamp":1763035620,"startTime":"0","endTime":"0","summary":" 11月13日，在上海证券交易所国际投资者大会的圆桌论坛上，嘉宾们围绕“中国能否诞生世界级的医药企业？” 杭州奥泰生物技术股份有限公司董事长、总经理高飞表示，世界级企业在中国“肯定会出现”。他表示，生物医药企业要在全球产生价值，必须先在中国市场形成价值基础，而国家在政策端的持续支持至关重要。 现场讨论认为，随着创新能力提升、政策不断完善，中国医药产业未来有望孕育世界级的一流企业。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-11-13/doc-infxhkcu5227361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1997245094.SGD","LU1064131003.USD","LU2328871848.SGD","LU2580892862.HKD","LU2097828557.USD","BK0239","BK0060","688293","LU2580892789.USD","LU1146622755.USD","LU1969619763.USD","LU0359201612.USD","BK0012","LU1023057109.AUD","LU0359201885.HKD","LU0405327148.USD","LU1328615791.USD","688606","LU2097828631.EUR","LU2543165471.USD","BK0216","LU2097828805.USD","BK1191","LU0359202008.SGD","LU1255011170.USD","BK0183","01276","BK0028","BK0196","LU2495084118.USD","LU2148510915.USD","LU1997245177.USD","LU1580142542.USD","LU1820825898.SGD","LU1997244956.HKD","LU2488822045.USD","LU2097828714.EUR","600276","LU0405327494.USD","LU2097828474.EUR","LU2289578879.USD","LU1064130708.USD","BK0188","LU1781817850.SGD","LU1655091616.SGD"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1764912590602,"stockEarnings":[{"period":"1week","weight":-0.0135},{"period":"1month","weight":-0.0108},{"period":"3month","weight":-0.1548},{"period":"6month","weight":0.1385},{"period":"1year","weight":0.2443},{"period":"ytd","weight":0.3392}],"compareEarnings":[{"period":"1week","weight":0.0001},{"period":"1month","weight":-0.0213},{"period":"3month","weight":0.0166},{"period":"6month","weight":0.1449},{"period":"1year","weight":0.1519},{"period":"ytd","weight":0.1563}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"397246人(较上一季度增加8.94%)","perCapita":"16058股","listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","registeredCapital":"663719万元","survey":" 江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是硫培非格司亭注射液、马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇胺片、碘佛醇注射液。","listedPrice":11.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,600276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}